We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Marlowe Plc | MRL | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 6.00 | 1.90% | 321.00 | 10:34:17 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 320.50 | 319.50 | 321.00 | 321.00 | 315.00 |
| Industry Sector |
|---|
| GENERAL FINANCIAL |
| Announcement Date | Type | Currency | Dividend Amount | Ex Date | Record Date | Payment Date |
|---|---|---|---|---|---|---|
| 22/05/2024 | Special | GBP | 1.55 | 13/06/2024 | 14/06/2024 | 05/07/2024 |
| Top Posts |
|---|
Posted at 26/9/2024 13:28 by dr biotech Its a bit odd - OPT started well and fell whilst MRL started badly and rose. Seems the TIC side is valued higher. I think we are down a few pence today overall (using the bid prices). Don't think I'll hold either for that long though, both a bit dull, although that has some appeal of its own |
Posted at 12/9/2024 15:30 by euclid5 The Optima Health executive management team will be subscribing for new ordinary shares in Optima Health following the Demerger and immediately prior to Admission at an Optima Health equity valuation of £225 million.The Demerger will be implemented by way of a dividend in specie of ordinary shares in the capital of Optima Health ("Optima Health Ordinary Shares") to Marlowe shareholders (the "Demerger Dividend") such that each shareholder of Marlowe shall receive: 1 Optima Health Ordinary Share for every 1 existing Marlow ordinary share |
Posted at 12/9/2024 15:22 by euclid5 Good rns today |
Posted at 05/7/2024 07:36 by plasybryn Dividend pay day i believe. Will some be reinvested pushing share price higher? |
Posted at 22/2/2024 20:55 by dr biotech They may be able to do a "return of capital" rather than a dividend as this would be funded by a sale rather than earnings. I'm not 100% sure on this but the tax rules would make it more beneficial. Makes little difference if you hold them in an ISA or SIPP as I do.Difficult to value the remaining business. Wouldn't surprise me if that gets sold off too later in the year. They probably couldn't get the reported 600m but 500m may be possible (yes I am just waving my finger in the air) which would give a total return of about 700p. Doubt I'll remain a LTH here - its one of my few successful trading shares though of course I should have sold out at much higher levels. Still its been a decent gain over the last two days. |
Posted at 15/6/2023 19:34 by dunns_river_falls Interesting given the mcap of MRL is £570m |
Posted at 20/1/2022 15:07 by dr biotech Always difficult to know here whether the price drop is due to the deal or just the fundraising (or a bit of both). Seems sensible enough - if somewhat larger than normal than the typical size for MRL. They shrugged off the failed aquistion of renew, hopefully today just a temporary dipBeen a largely plain sailing ride for the last 8 or so months. |
Posted at 01/12/2021 16:41 by km18 Marlowe is a leading and highly innovative software services firm, providing risk and compliance advice, as well as testing and inspection expertise. As a result, the corporation is involved in the provision of risk assessments, and maintenance of security systems, with the purpose of optimising engineering services while mitigating software technical issues on behalf of clients. Consequently, a wide variety of stakeholders are interested in the firm’s ability to derive capital and re-invest cash into organic growth, yielding substantial returns for investors. This evidence is supported by the equity rally of £128.1m (£266.3m-£138.2m) with respect to last year. Additionally, the software service firm was able to effectively fund its operations, since the firm’s net cashflow soared from £9.4m to £58.8m. Today, Marlowe released its financial results, where adjusted profit before tax surged 127% to £15.2m, illustrating the effectiveness of the firm’s business model and corporate investment strategy. |
Posted at 20/10/2021 11:37 by wad collector Another acquisition, this time with a £50M placing @ 907p. |
Posted at 22/2/2021 18:15 by masurenguy Marlowe growth plans to drive shares, says BerenbergSecurity systems provider Marlowe has set out ‘highly ambitious’ growth targets that Berenberg says could deliver serious upside. Analyst Calum Battersby reiterated his ‘buy’ recommendation and increased the target price from 660p to 900p. The company has announced targets over the next 3 years, including hitting £500m of revenue and £100m of earnings to be achieved ‘through a combination of 7% of organic growth per annum, 20% margins, 90% cash conversion and continuation of the group’s existing M&A strategy’, according to Battersby. ‘While clearly an aggressive target, we believe this can be achieved, given the company’s track record to date, and the scale of opportunities that already exist in its various end-markets,’ he said. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
